Free Trial

Protagonist Therapeutics (PTGX) Earnings Date, Estimates & Call Transcripts

Protagonist Therapeutics logo
$99.21 -0.31 (-0.31%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$106.40 +7.20 (+7.25%)
As of 08:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protagonist Therapeutics Earnings Summary

Protagonist Therapeutics released Q4 2025 earnings on February 25, 2026, reporting an EPS of -$0.69, which missed analysts' consensus estimates of -$0.53 by $0.16. Quarterly revenue was reported to be $7.44 million, below analyst estimates of $14.92 million. With a trailing EPS of -$2.05, Protagonist Therapeutics' earnings are expected to decrease next year, from $1.02 to ($1.59) per share.

Upcoming
Earnings Date
May. 6Estimated
Consensus EPS
(Feb. 25)
-$0.53
Actual EPS
(Feb. 25)
-$0.69 Missed By -$0.16
Actual Revenue
(Feb. 25)
$7.44M

Q4 2025 Earnings Resources

PTGX Upcoming Earnings

Protagonist Therapeutics' Q1 2026 earnings is estimated for Wednesday, May 6, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, May 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Get Protagonist Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

PTGX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PTGX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Protagonist Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20262-$0.70-$0.69-$0.70
Q2 20262$1.98$5.60$3.79
Q3 20262$0.49$3.60$2.05
Q4 20262-$0.71-$0.13-$0.42

Protagonist Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026-$0.65--$0.05$12.21M-
2/25/2026Q4 2025-$0.53-$0.69 -$0.16-$0.69$14.92M$7.44M
11/6/2025Q3 2025-$0.59-$0.62 -$0.03-$0.62$5.41M$4.71M
8/6/2025Q2 2025-$0.53-$0.55 -$0.02-$0.55$8.32M$5.55M
5/6/2025Q1 2025-$0.50-$0.19+$0.31-$0.19$30.44M$28.32M
2/21/2025Q4 2024-$0.09$1.98+$2.07$1.98$56.65M$170.64M
11/7/2024--$0.59-$0.54+$0.05-$0.54$4.50M$4.68M
8/6/2024--$0.50-$0.50--$0.50$40.00M$4.17M
5/7/2024Q1 2024$2.51$3.26+$0.75$3.26$300.00M$254.95M

Data powered by Fiscal.ai.

Protagonist Therapeutics Earnings - Frequently Asked Questions

Protagonist Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 6th, 2026 based off last year's report dates. Learn more on PTGX's earnings history.

In the previous quarter, Protagonist Therapeutics (NASDAQ:PTGX) missed the analysts' consensus estimate of ($0.53) by $0.16 with a reported earnings per share (EPS) of ($0.69). Learn more on analysts' earnings estimate vs. PTGX's actual earnings.

Protagonist Therapeutics (NASDAQ:PTGX) has a recorded annual revenue of $46.02 million.

Protagonist Therapeutics (NASDAQ:PTGX) has a recorded net income of -$130.15 million. PTGX has generated -$2.05 earnings per share over the last four quarters.

Protagonist Therapeutics' earnings are expected to decrease from $1.02 per share to ($1.59) per share in the next year.


This page (NASDAQ:PTGX) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners